Cochlear and Vestibular Effects of Combined Intratympanic Gentamicin and Dexamethasone

Enis Alpin Güneri, Yüksel Olgun, Mustafa Aslier, Daniele Nuti, Gûnay Kırkım, Serpil Mungan, Efsun Kolatan, Safiye Aktaş, Franco Trabalzini, Hülya Ellidokuz, Osman Yılmaz, Marco Mandala

Department of Otorhinolaryngology, Dokuz Eylül University School of Medicine, İzmir, Turkey (EAG, YO, MA)
Department of Otology and Skull Base, Azienda Ospedaliera Universitaria Senese, Siena, Italy (DN, FT, MM)
Department of Otorhinolaryngology, Dokuz Eylül University School of Medicine Unit of Hearing Speech and Balance, İzmir, Turkey (GK, SM)
Department of Laboratory of Animal Science, Dokuz Eylül University School of Medicine, İzmir, Turkey (EK, OY)
Department of Basic Oncology, Dokuz Eylül University Institute of Oncology, İzmir, Turkey (SA)
Department of Biostatistics, Dokuz Eylül University School of Medicine, İzmir, Turkey (HE)

OBJECTIVE: The aim of this study is to evaluate the effects of an intratympanic gentamicin-dexamethasone combination on the inner ear.

MATERIALS and METHODS: Twenty-six Wistar albino rats were divided into four groups: Group I (Control), group II (Intratympanic dexamethasone; ITD), group III (Intratympanic gentamicin; ITG), and group IV (Intratympanic gentamicin and dexamethasone; ITGD). On the first day after basal auditory brainstem response (ABR) measurements, the ITG group received 0.03 mL of intratympanic gentamicin (26.7 mg/mL). Intratympanic injection of 0.06 mL of a solution containing 13.35 mg/mL gentamicin and 2 mg/mL dexamethasone was performed in the ITGD group. 0.03 mL of physiological intratympanic serum and dexamethasone (4 mg/mL) was applied in control and ITD groups, respectively. On the 7th day, ABR measurements were repeated and vestibular functions were evaluated. On the 21th day, ABR and vestibular tests were repeated, and the animals were sacrificed for histopathological investigation.

RESULTS: The ITG group's hearing thresholds deteriorated in all frequencies. The ITGD group's hearing thresholds were significantly better than the ITG group, except at 8 kHz on the 7th day and in all frequencies at the 21th day measurements. The vestibular function scores of the ITG and ITGD groups were higher than the controls. Apoptotic changes were seen in cochlea, spiral ganglion, and vestibule of the ITG group. Cochlear and vestibular structures were well preserved in the ITGD group, similar to the controls.

CONCLUSION: The ITGD combination led to a significant hearing preservation. Although in subjective vestibular tests, it seemed that vestibulotoxicity was present in both ITG and ITGD groups the histopathological investigations revealed no signs of vestibulotoxicity in the ITGD group in contrast to the ITG group. Further studies using a combination of different concentrations of gentamicin and dexamethasone are needed.

KEYWORDS: Gentamicin, dexamethasone, intratympanic

INTRODUCTION
Intratympanic gentamicin (ITG) is an effective treatment method for the vestibular symptoms of Meniere’s Disease (MD). Although gentamicin is mainly toxic to the vestibule, ototoxicity is an important concern and can be encountered in up to 34% of the treated patients depending on the dose regimen and number of injections [1]. Different ITG application protocols have been described recently in order to achieve complete or substantial vertigo control with minimal risk of ototoxicity [2-6]. Despite these efforts, ITG is not an ideal treatment option for patients with serviceable hearing and/or bilateral MD.

Intratympanic steroid (ITS) application has a role in the treatment of bilateral MD patients since most of these cases have underlying autoimmune etiology and respond well to steroids. Although ITS applications may seem more appropriate for patients with serviceable hearing and bilateral MD, vertigo control rates are not as high as those obtained with ITG treatments [7, 8].

An ideal therapy for MD patients should provide both high vertigo control rates with hearing preservation. The aim of this study is to evaluate the effects of a combined gentamicin and dexamethasone intratympanic application on the inner ear.

MATERIALS and METHODS
The protocol of this study has been approved by the local ethical committee of the university’s animal care and use department (protocol number: 23/2014).
Twenty-nine adult female Wistar albino rats, weighing 200 g to 300 g, were divided randomly into four groups. The groups were consisted as follows: Group I was composed of 7 animals that received a single 0.03 mL of intratympanic saline injection as the control.

Group II was composed of 7 animals that received a single 0.03 mL of intratympanic dexamethasone (4 mg/mL) injection (ITD group). Group III was composed of 7 animals that received a single 0.03 mL of intratympanic gentamicin (26.66 mg/mL) injection (ITG group). Group IV was composed of 8 animals that received a single injection of 0.06 mL of a solution with 13.35 mg/mL gentamicin and 2 mg/mL dexamethasone combination intratympanically (ITGD group).

For the ITG group, a solution was formed by a mixture of 1 mL (40 mg/mL) gentamicin and 0.5 mL sodium bicarbonate in order to reach a final gentamicin concentration of 26.6 mg/mL. Then, 0.03 mL of this solution was applied. In the ITGD group, we prepared a combination solution by mixing 1 mL gentamicin (40 mg/mL), 0.5 mL sodium bicarbonate, and 1.5 mL dexamethasone (4 mg/mL). Then, a final concentration of 13.3 mg gentamicin and 2 mg/mL dexamethasone was obtained and 0.06 mL of this solution was applied. In this way, in the ITGD group, we were able inject the same quantities of dexamethasone and gentamicin as in the ITD and ITG groups. Injection of the same quantity of gentamicin and dexamethasone in 0.03 mL would require the use of a 80 mg/mL gentamicin preparation and 8 mg/mL dexamethasone preparation. Although 80 mg/mL gentamicin exists on the market, a form of 8 mg/mL dexamethasone does not exist in the market, at least in our country. For this reason, in the combination group, we used a higher volume in order to reach the same quantity of gentamicin and dexamethasone.

The animals were kept in controlled conditions with 12 hour light/dark cycles. All of them had access to standard rat pellet food and tap water. They underwent otomicroscopic examination at the beginning of the study and before each audiological examination. One animal from the control group and one animal from the ITD group were excluded from the study due to otitis media, and one animal from the ITD group was excluded due to tympanic membrane perforation determined just before the second audiological examination. Animals showing any signs of external or middle ear disorders were excluded from the study.

Animals were anesthetized with 40 mg/kg ketamine hydrochloride (Pfizer, NY, USA) and 5 mg/kg xylazine hydrochloride (Sigma-Aldrich, Lyon, France) prior to all injections and audiological measurements. On the first day of the study, baseline auditory brainstem responses (ABR) were obtained. After that, a single intratympanic injection was performed through the anterosuperior portion of the right tympanic membrane of all rats under otomicroscopy.

Auditory Assessment
Evoked responses to 1024 tone presentations were averaged using an Intelligent Hearing System (IHS, Miami, FL) with the Smart-EP 10 version software. Subdermal needles were used as electrodes (Model F-EZ, Astro-Med Inc., Rhode Island). The active electrode was inserted at the vertex, the reference electrode ventrolateral to the left ear, and the ground electrode was inserted ventrolateral to the right ear. A pair of high frequency transducers were coupled with the IHS system to generate specific acoustic stimuli that were presented at a rate of 37.1 per second. ABR thresholds were measured in response to toneburst stimuli with 1 ms rise/fall and 0 ms plateaus, gated by a Blackman envelope, and centered at frequencies of 4, 8, 12, 16, and 32 kHz. Evoked potentials were band-pass-filtered between 30 and 3000 Hz. Animals were presented with a stimulus intensity series, which was initiated at 80 dB SPL and reached to a minimum of 10 dB SPL. The intensity of the stimulus was varied in a 10 dB stepwise decrement. Each ear was tested separately for the ABR threshold, which was defined as the lowest intensity capable of eliciting a replicable and visually detectable wave II. ABR measurements were performed on the 1st, 7th, and 21st day of study.

Analyses of Vestibular Function
Vestibular functions were evaluated on the 7th and 21st days of the study, just before the second and third ABR measurements, by evaluating tail hanging and air righting reflexes and swimming tests.

In the tail hanging reflex test, rats with normal vestibular function are expected to extend their forelimbs when lifted by their tails. But in case of a vestibular impairment, they bend and sometimes even crawl toward their tails 

Statistical Analysis
Statistical analysis was performed using the SPSS 15.0 software package for Windows (Statistical Package for Social Sciences; SPSS Inc.;
Chicago, IL, USA). Results were presented as means and standard deviations (SD). All data were analyzed by one-way analysis of variance (ANOVA) post-hoc Bonferroni test and p<0.05 was considered as a statistically significant difference between measurements.

RESULTS

Auditory Assessment
Baseline ABR values were not significantly different between groups (p>0.005). However, hearing thresholds of the ITG group deteriorated in all frequencies when compared with the control group in both the second and third ABR measurements (p<0.05). In the ITG group, hearing thresholds were also worse than the ITD group in all frequencies in the second and third ABR measurement, except at 4 kHz (p<0.05) (Figure 1, 2).

The hearing thresholds of the ITGD group were better than the ITG group for all frequencies except for 8 kHz in the second ABR measurement (p<0.05). The third ABR measurements revealed that hearing thresholds of the ITGD group were better than the ITG group for all frequencies (p<0.05). In contrast to the ITG group, no statistically significant differences were found between the ITGD, ITD, and control groups in any of the ABR measurements (p>0.05) (Figure 1, 2).

Vestibular Findings
Vestibular dysfunction scores of the ITG and ITGD groups showed no statistically significant differences (p>0.05). Vestibular dysfunction scores of the ITG and ITGD groups were higher than both the control and ITD groups (p<0.05). Those differences were mainly due to the pathological responses obtained from swimming and tail hanging reflexes. No pathological responses concerning air righting reflexes were seen in any of the animals. Vestibular dysfunction scores of the ITD and control groups were not significantly different (p>0.05) (Figure 3-5).

Histopathological Findings
The organ of Corti, spiral ganglion, and vestibule specimens of the control group were morphologically normal with light microscopy examination. No apoptotic cells were detected by TUNEL staining in these groups. In the ITG group, pyknotic spiral ganglion cells were seen in light microscopy examination. Although light microscopy findings in the cochlea and vestibule of the ITG group seemed morphologically normal, apoptotic changes were evident in the cochlea, spiral ganglion, and vestibule specimens with TUNEL staining. These

Figure 1. Mean ± SD of the ABR thresholds on the 7th day of the study. ABR: Auditory brainstem response; SD: standard deviations

Figure 2. Mean ± SD of the ABR thresholds on the 21st day of the study. ABR: Auditory brainstem response; SD: standard deviations

Figure 3. a, b. Swimming test. Control group rats were able to swim without any problems (a). Rats with vestibular impairment sink or have difficulties in swimming (b).

Figure 4. a, b. Tail hanging reflex. Rats with normal vestibular function extend their forelimbs when lifted by their tails (a). In the case of a vestibular impairment, they bend toward their tails (b).
apoptotic changes were especially more severe in the spiral ganglion cells. Cochlear and vestibular structures were well preserved in the ITGD group, similar to the control and ITD groups. Apoptotic spiral ganglion cells decreased in the ITGD group when compared with the ITG group (p=0.001, Kruskal Vallis test; p=0.04 Mann Whitney U test with Bonferoni correction) (Figures 6-11).

DISCUSSION
Meniere’s Disease is characterized by vertigo attacks, hearing loss, aural fullness, and tinnitus. Dietary salt restriction, diuretics, and betahistine are considered as the first-line treatment options. ITG therapy is preferred for patients with intractable vertigo attacks, especially for those with poor hearing. Gentamicin acts as a vestibulotoxic agent by destroying endolymph producing dark cells in the planum semilunatum of the crista ampullaris. High rates of complete or substantial vertigo control (over 85%) are achieved in many studies concerning ITG treatments [11-13]. Ototoxicity, which was a threat with former treatments using higher doses and titration protocols, can still be encountered rarely due to the cumulative effect of gentamicin [1], thus hindering its common use. Moreover, it has been shown that even a single dose of gentamicin may cause ototoxicity in some cases as a result of idiosyncrasy [14].

Many different intratympanic injection protocols have been used in order to achieve substantial or complete vertigo control with hearing preservation. As it is known, post treatment vertigo reporting standards were described by the American Academy of Otolaryngol-
ogy—Head and Neck Surgery (AAO-HNS) committee on Hearing and Equilibrium (CHE) guidelines [15]. While the term “complete vertigo control” was defined as total absence of vertigo spells during a period of 24 months after treatment, “substantial vertigo control” was defined as reaching a ratio score between 1 and 40 in the comparison of mean vertigo spells in a period of 24 months after treatment with the mean number of vertigo spells 6 months before treatment.

In a recent meta-analysis on ITG injection protocols, Chia et al. [1] reported that weekly gentamicin injection protocols led to a mild ototoxicity rate compared to other protocols; but even in that case, the incidence of ototoxicity was as high as 13.1%. However, severe ototoxicity up to 34.7% was reported with daily multiple injection protocols [1]. In another study in which gentamicin-soaked pledgets were placed in the round window niche, complete or substantial vertigo control was achieved in 88.5% of the patients, but varying degrees of significant hearing impairments occurred in 12 out of 24 patients (50%), including 4 total sensorineural hearing losses [13]. Light et al. [16] suggested that there is a correlation between the degree of vestibular ablation, the control of vertigo, and the risk of hearing loss; and they claimed that low dose gentamicin treatment given in long intervals offers minimum risk in terms of hearing loss.

Immunologic factors may also play an important role in the pathophysiology of MD. Otoimmune responses to type II collagen [17], deposits of IgG [17], and mononuclear cell infiltrations on the endolymphatic sac [18] have all been demonstrated on postmortem studies. Thus, anti-inflammatory and immunomodulatory effects of steroids have come into use for the treatment of MD. Akkuzu et al. [8] compared the effects of ITD and ITG in patients with MD and found that complete vertigo control rates that were achieved with ITG were significantly higher than those with ITD (92% versus 67%). In another similar study, the complete vertigo control rate was 82.9% in the ITG group in contrast to 48.1% in the ITD group [7]. In another study using ITS for the treatment of MD patients, complete vertigo control was achieved in less than half of the cases [19]. Former similar studies have demonstrated that dexamethasone has a limited vertigo control potential in MD patients [7, 8, 19].

Studies concerning combination therapies on MD treatment are quite limited. In a study conducted on 299 MD patients, all cases were treated with intratympanic injections of a combination solution of streptomycin (10 mg/mL) and dexamethasone (24 mg/mL) in addition to systemic dexamethasone (16 mg) for 3 consecutive days. This treatment protocol was repeated up to three times in patients with intractable symptoms. The authors used the MD Outcome Questionnaire survey to analyze treatment outcomes. Although they reported that 88% of the patients had improvements in their “vertigo subscore”, a considerable amount of hearing loss (17.9%) occurred in these patients [20].
We think that an ideal combination therapy should incorporate the beneficial effects of both agents while minimizing their side effects. Our aim was to obtain an ideal treatment result by combining gentamicin, which has a powerful effect on vertigo control, with dexamethasone, which has a proven otoprotective effect. In the English literature, there were no studies evaluating the effects of combined intratympanic application of gentamicin and dexamethasone. Our study revealed that gentamicin significantly reduced the hearing thresholds for all frequencies in both early and late audiological assessments. Histopathological findings in the ITG group were correlated with the ABR findings showing apoptosis in the cochlea and spiral ganglion cells. Vestibulotoxic effects of gentamicin were also confirmed by both vestibular and histopathological assessments. In the ITGD group, hearing was significantly protected in all frequencies, except at 8 kHz in the early ABR assessment. In the third ABR measurements, hearing thresholds of the ITGD group were better than the ITG group for all frequencies. TUNEL stainings of the ITGD group also revealed less apoptosis in the cochlea and spiral ganglion cells in contrast to the ITG group. In the ITGD group, although vestibular dysfunction scores were similar to the ITG group, histopathological findings of vestibular toxicity were not evident. Therefore, we think that the desired vestibulotoxic effect of gentamicin is somehow minimized when combined with dexamethasone, so that were not able to show the histopathological signs of vestibulotoxicity, although clinical findings clearly existed. Further studies using more sensitive histopathological methods, such as electron microscopy, as well as using a combination solution containing a higher concentration of gentamicin and/or a lesser concentration of dexamethasone might be more appropriate for demonstrating the vestibulotoxic effects. We also think that the efficacy of the intratympanic gentamicin-dexamethasone combination should be re-evaluated in hydrops models.

We observed that the ITGD combination led to a significant preservation of the hearing thresholds of rats in contrast to ITG application (p<0.05). Although subjective vestibular tests pointed to possible vestibulotoxic effects for both ITG and ITGD groups, histopathological results revealed no signs of vestibulotoxicity in the ITGD group in contrast to the ITG group. We concluded that combined ITGD application may be less harmful to the hearing of MD patients by protecting against otoxicity. Since the positive clinical signs of the vestibulotoxic effect of ITGD combination was not supported with the histological results obtained in this study, one may assume that the clinical effect may not be correlated with the morphological changes in the vestibule. Another possibility is that combined ITGD may prevent vestibulotoxicity, at least with the dose and treatment regimen used in this study. Further studies using combinations of different concentrations of gentamicin and dexamethasone may be helpful to find an optimum combination that has a maximum vestibulotoxic and minimum otoxic effect.

**Ethics Committee Approval:** Ethics committee approval was received for this study from the ethics committee of Dokuz Eylül University for animal care and use.

**Informed Consent:** N/A.

**Peer-review:** Externally peer-reviewed.


**Conflict of Interest:** No conflict of interest was declared by the authors.

**REFERENCES**

5. Seidman M. Continuous gentamicin therapy using an IntraEar microcatheter for Meniere’s disease: a retrospective study. Otolaryngol Head and Neck Surg 2002; 126: 244-56. [CrossRef]